Research

WO17299

Research

First-line Herceptin® alone or in combination with a taxane in patients with metastatic breast cancer who relapsed after receiving adjuvant Herceptin® for HER2-positive early breast cancer

An open-label study of the effect of first-line Herceptin® alone or in combination with a taxane on tumor response and disease progression in patients with metastatic breast cancer who relapsed after receiving adjuvant Herceptin® for HER2-positive early breast cancer.